Cargando…

Novel concepts in atrial fibrillation ablation—breaking the trade‐off between efficacy and safety

Despite substantial technological and procedural advances that have improved the efficacy and safety of AF ablation in recent years, the long‐term durability of ablation lesions is still not satisfactory. There also remains concern regarding rare but potentially life‐threatening procedure‐related co...

Descripción completa

Detalles Bibliográficos
Autores principales: Althoff, Till F., Mont, Lluís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339092/
https://www.ncbi.nlm.nih.gov/pubmed/34386116
http://dx.doi.org/10.1002/joa3.12592
_version_ 1783733522704367616
author Althoff, Till F.
Mont, Lluís
author_facet Althoff, Till F.
Mont, Lluís
author_sort Althoff, Till F.
collection PubMed
description Despite substantial technological and procedural advances that have improved the efficacy and safety of AF ablation in recent years, the long‐term durability of ablation lesions is still not satisfactory. There also remains concern regarding rare but potentially life‐threatening procedure‐related complications like cardiac tamponade and atrioesophageal fistulae. Current ablation strategies are aiming to optimize the trade‐off between efficacy and safety, where more extensive ablation appears to inevitably increase the risk of collateral injury. However, new forms of energy application may have the potential to resolve this quandary. The emerging concept of high power‐short duration radiofrequency ablation features a more favorable lesion geometry that appears ideally suited to create contiguous lesions in the thin‐walled atrium. Moreover, novel non‐thermal ablation methods based on electroporation appear to provide a unique selectivity for cardiomyocytes and to spare surrounding tissues composed of other cell types. Both, high power‐short duration and electroporation ablation might have the potential to break the trade‐off between effective lesions and collateral damage and to substantially improve risk‐benefit ratios in AF ablation. In addition, both approaches lead to considerable reductions in ablation times. However, their putative benefits regarding efficacy, efficiency, and safety remain to be proven in randomized controlled trials.
format Online
Article
Text
id pubmed-8339092
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83390922021-08-11 Novel concepts in atrial fibrillation ablation—breaking the trade‐off between efficacy and safety Althoff, Till F. Mont, Lluís J Arrhythm Clinical Reviews Despite substantial technological and procedural advances that have improved the efficacy and safety of AF ablation in recent years, the long‐term durability of ablation lesions is still not satisfactory. There also remains concern regarding rare but potentially life‐threatening procedure‐related complications like cardiac tamponade and atrioesophageal fistulae. Current ablation strategies are aiming to optimize the trade‐off between efficacy and safety, where more extensive ablation appears to inevitably increase the risk of collateral injury. However, new forms of energy application may have the potential to resolve this quandary. The emerging concept of high power‐short duration radiofrequency ablation features a more favorable lesion geometry that appears ideally suited to create contiguous lesions in the thin‐walled atrium. Moreover, novel non‐thermal ablation methods based on electroporation appear to provide a unique selectivity for cardiomyocytes and to spare surrounding tissues composed of other cell types. Both, high power‐short duration and electroporation ablation might have the potential to break the trade‐off between effective lesions and collateral damage and to substantially improve risk‐benefit ratios in AF ablation. In addition, both approaches lead to considerable reductions in ablation times. However, their putative benefits regarding efficacy, efficiency, and safety remain to be proven in randomized controlled trials. John Wiley and Sons Inc. 2021-07-09 /pmc/articles/PMC8339092/ /pubmed/34386116 http://dx.doi.org/10.1002/joa3.12592 Text en © 2021 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Reviews
Althoff, Till F.
Mont, Lluís
Novel concepts in atrial fibrillation ablation—breaking the trade‐off between efficacy and safety
title Novel concepts in atrial fibrillation ablation—breaking the trade‐off between efficacy and safety
title_full Novel concepts in atrial fibrillation ablation—breaking the trade‐off between efficacy and safety
title_fullStr Novel concepts in atrial fibrillation ablation—breaking the trade‐off between efficacy and safety
title_full_unstemmed Novel concepts in atrial fibrillation ablation—breaking the trade‐off between efficacy and safety
title_short Novel concepts in atrial fibrillation ablation—breaking the trade‐off between efficacy and safety
title_sort novel concepts in atrial fibrillation ablation—breaking the trade‐off between efficacy and safety
topic Clinical Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339092/
https://www.ncbi.nlm.nih.gov/pubmed/34386116
http://dx.doi.org/10.1002/joa3.12592
work_keys_str_mv AT althofftillf novelconceptsinatrialfibrillationablationbreakingthetradeoffbetweenefficacyandsafety
AT montlluis novelconceptsinatrialfibrillationablationbreakingthetradeoffbetweenefficacyandsafety